COC Comment: Research on New Doxycycline Derivative

Frontiers | A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity | Oncology

Read the article Here

“This is very exciting and important research, which we believe holds real promise.

However, as with the development of any new chemical entity, further work must first be completed, including human pharmacokinetics, and toxicology, before a new drug could reach the market. We would like to wish Prof Lisanti and his team all the very best taking this project forward.
In the meantime, patients continue to seek out treatments which could benefit them today.

As highlighted by this paper, existing, licensed Doxycycline is a known cancer stem cell inhibitor and potentially potent antimetastatic agent in its own right, particularly when administered as one component of a comprehensive adjunctive combination (the COC Protocol) aimed at disrupting and weakening the overall metabolic machinery of abnormal cells.

Doxycycline is a bacteriostatic rather than bactericidal antibiotic, meaning it stops bacteria from reproducing while not necessarily killing them. It is generally believed to be less disruptive to gut bacteria than other classes of antibiotics and studies show it is almost completely absorbed in the upper gastrointestinal tract.

Furthermore, it is safely taken over the long-term as prophylaxis in chronic lung conditions such as COPD and also in malaria. At Care Oncology we seek to further limit overt antibacterial effects by pulsing cycles of Doxycycline at intervals rather than administering it continuously.